Paraoxonase 1 and atherosclerosis-related diseases

被引：61

作者：

Kotur-Stevuljevic, Jelena ^{[1
]}

Vekic, Jelena ^{[1
]}

Stefanovic, Aleksandra ^{[1
]}

Zeljkovic, Aleksandra ^{[1
]}

Ninic, Ana ^{[1
]}

Ivanisevic, Jasmina ^{[1
]}

Miljkovic, Milica ^{[1
]}

Sopic, Miron ^{[1
]}

Munjas, Jelena ^{[1
]}

Mihajlovic, Marija ^{[1
]}

Spasic, Slavica ^{[1
]}

Jelic-Ivanovic, Zorana ^{[1
]}

Spasojevic-Kalimanovska, Vesna ^{[1
]}

机构：

[1] Univ Belgrade, Fac Pharm, Dept Med Biochem, POB 146, Belgrade 11000, Serbia

来源：

BIOFACTORS | 2020年 / 46卷 / 02期

关键词：

atherosclerosis; cancer; cardiovascular disease; diabetes; HDL dysfunction; paraoxonase; 1; renal disease; stroke; HIGH-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; APOLIPOPROTEIN-A-I; OBSTRUCTIVE PULMONARY-DISEASE; HDL PARTICLE-SIZE; OXIDATIVE STRESS; DIABETES-MELLITUS; PON1; ACTIVITY; HEART-DISEASE; CARDIOVASCULAR-DISEASE;

D O I：

10.1002/biof.1549

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A direct and an indirect relationship between paraoxonase 1 (PON1) and atherosclerosis exists. Given PON1's physical location within high-density lipoprotein (HDL) particles and its recognized enzyme activity, it is certainly reasonable to suggest that PON1 facilitates the antiatherogenic nature of HDL particles. PON1 also plays a role in regulating reverse cholesterol transport, antioxidative, anti-inflammatory, antiapoptotic, vasodilative, and antithrombotic activities and several endothelial cell functions. HDL dysfunctionality is a more recent issue and seems to be centered on pathological conditions affecting HDL structure and size profiles. This review is focused on the role of PON1 status in different atherosclerosis-related diseases that we have studied over the last twenty years (coronary heart disease, acute ischemic stroke, diabetes mellitus type 2, end-stage renal disease, chronic obstructive pulmonary disease, and sarcoidosis) with the aim to determine the true value of PON1 as a biomarker. The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features.

引用

页码：193 / 205

页数：13

共 139 条

[21] Paraoxonase 1 (PON1) Q192R genotypes and their interaction with smoking strongly increase atherogenicity and the Framingham risk score [J].

de Souza-Nogueira, Andre ;

Camargo, Alissana Ester ;

Remondi, Felipe Assan ;

Bastos Paoliello, Monica Maria ;

Richter, Rebecca J. ;

Furlong, Clement E. ;

Barbosa, Decio Sabbatini ;

Maes, Michael ;

Moreira, Estefania Gastaldello .

ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2016, 60 (05) :426-435

[22] Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells [J].

Deakin, S ;

Moren, X ;

James, RW .

ATHEROSCLEROSIS, 2005, 179 (01) :17-25

[23] Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphism C-107T and statin [J].

Deakin, Sara ;

Guernier, Sophie ;

James, Richard W. .

PHARMACOGENETICS AND GENOMICS, 2007, 17 (06) :451-457

[24] HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity [J].

Deakin, Sara ;

Moren, Xenia ;

James, Richard W. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (05) :1146-1152

[25] Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischernic stroke [J].

Demirdogen, Birsen Can ;

Turkanoglu, Aysun ;

Bek, Semai ;

Sanisoglu, Yavuz ;

Demirkaya, Seref ;

Vural, Okay ;

Arinc, Emel ;

Adali, Orhan .

CLINICAL BIOCHEMISTRY, 2008, 41 (1-2) :1-9

[26] A Genetic Biomarker of Oxidative Stress, the Paraoxonase-1 Q192R Gene Variant, Associates with Cardiomyopathy in CKD: A Longitudinal Study [J].

Dounousi, E. ;

Bouba, I. ;

Spoto, B. ;

Pappas, K. ;

Tripepi, G. ;

Georgiou, I. ;

Tselepis, A. ;

Elisaf, M. ;

Tsakiris, D. ;

Zoccali, C. ;

Siamopoulos, K. .

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2016, 2016

[27] Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities [J].

Draganov, DI ;

Teiber, JF ;

Speelman, A ;

Osawa, Y ;

Sunahara, R ;

La Du, BN .

JOURNAL OF LIPID RESEARCH, 2005, 46 (06) :1239-1247

[28] Pharmacogenetics of paraoxonases: a brief review [J].

Draganov, DI ;

La Du, BN .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 (01) :78-88

[29] Serum paraoxonase-1 activity is more closely related to HDL particle concentration and large HDL particles than to HDL cholesterol in Type 2 diabetic and non-diabetic subjects [J].

Dullaart, Robin P. F. ;

Otvos, James D. ;

James, Richard W. .

CLINICAL BIOCHEMISTRY, 2014, 47 (12) :1022-1027

[30]

Elnoamany MF., 2014, WORLD J CARDIOVASC D, V4, P465

← 1 2 3 4 5 6 7 8 9 10 →